Story
Mercari Stock Falls Over 5% on Pokémon Card Resale Ban
Summary
Shares of the Japanese e-commerce firm declined after it announced a ban on reselling certain popular Pokémon cards, raising concerns about lost transaction volume amid a broader market downturn.
Shares of Japanese e-commerce platform Mercari (TYO:4385) fell sharply in Wednesday trading, closing down 5.4% at ¥3,658. The decline was driven by investor reaction to the company's decision to ban certain high-demand Pokémon products from its platform, coupled with wider negative sentiment in the Japanese market.
Policy Change Sparks Concern
Mercari announced it will prohibit listings of products related to the upcoming 30th-anniversary Pokémon Card Game. The company stated the measure is intended to prevent disputes and harassment that have resulted from a surge in transactions during previous popular releases.
The policy specifically targets the practice of "scalping," where resellers buy new products in bulk and list them at inflated prices. While the ban is aimed at promoting a fairer marketplace, investors are concerned that Mercari could miss out on significant transaction volumes and the associated revenue from the highly anticipated launch.
AdBroader Market Pressures
Mercari's stock-specific issues were compounded by a broader downturn in the market. Japanese technology stocks experienced a general sell-off on Wednesday, weighing on investor sentiment.
Furthermore, the market is bracing for a key monetary policy decision from the Bank of Japan this Friday. Widespread expectations of an interest rate hike contributed to the cautious and risk-off mood among investors, adding to the pressure on equities like Mercari.
Read next
More on Stocks
BOJ Rate Hike Nears, Pitting Japanese Financials Against Exporters
The Bank of Japan is widely expected to raise its key interest rate to a 31-year high this week, a move that is creating a sharp divide in the stock market between beneficiaries like banks and sectors facing pressure, such as exporters.
Genscript Biotech Stock Surges Over 16% on Eli Lilly AI Partnership
Shares in the Hong Kong-listed biotech firm rallied after announcing a collaboration with Eli Lilly's AI-powered drug discovery platform, a move supported by a recent capital raise focused on AI infrastructure.
Volkswagen's Seat Brand Faces Discontinuation Amid Chinese EV Pressure
Volkswagen is reportedly set to phase out its historic Spanish brand, Seat, as part of a major restructuring to combat rising competition from Chinese automakers and focus investment on its profitable, all-electric Cupra marque.
Hong Kong Biotech Sector Shows Stark Divide as Biocytogen, Genscript Post Major Gains
A small group of companies, led by Biocytogen Pharmaceuticals and Genscript Biotech, have delivered substantial one-year returns, highlighting a sharp performance gap within Hong Kong's 52-stock biotech universe where most firms remain unprofitable.